Cowealth Medical China Co., Ltd. is a healthcare services and medical technology provider that specializes in in-vitro diagnostic supply chain integration, medical equipment distribution, and digital hospital empowerment solutions across Greater China. Founded in 1997 and headquartered in Shanghai, China, the company operates as a publicly listed subsidiary of Taiwan-based Cowealth Medical Holding Co., Ltd. and primarily serves tertiary Grade-A hospitals and healthcare institutions across Mainland China.
The company organizes its business operations across three core segments: In-Vitro Diagnostic Centralized Procurement Services, Medical Equipment Distribution, and Healthcare Enablement and Digital Solutions. Its product and service portfolio encompasses: centralized procurement, vendor-managed inventory, and supply chain logistics for multi-brand in-vitro diagnostic reagents and consumables, covering clinical chemistry, immunodiagnostics, hematology, point-of-care testing, molecular diagnostics, microbiology, and blood screening; agency distribution, import, installation, and technical support for advanced specialized medical devices, including radiation oncology equipment, ophthalmic diagnostic systems, and surgical apparatus; the Zhibeita hospital operational decision-support and financial integration software platform; the MetaVision digitized operating room audio-video integration platform for live surgical tele-mentoring, clinical teaching, and research; specialized artificial intelligence-driven diagnostic support systems for rheumatology and ocular surface diseases; and hospital management consulting alongside cross-strait medical academic exchange services.
In recent developments, Cowealth Medical China has accelerated its strategic transition from a conventional medical distributor to a technology-driven hospital empowerment partner through the rollout of its ACME service framework. The company has expanded commercial deployments of its proprietary Zhibeita healthcare management platform and MetaVision digital operating room systems across regional medical centers. In response to nationwide Volume-Based Procurement policies affecting diagnostic reagent pricing, the company restructured its centralized supply chain workflows, enhanced hospital-level SPD logistics management, and increased research and development investment to commercialize proprietary medical informatics software and clinical decision-support algorithms. Additionally, the company has broadened its partnerships with domestic hospital departments to deploy specialized clinical artificial intelligence diagnostic solutions, driving operational efficiency and supporting financial recovery across its core institutional customer base.